Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Department of Anesthesia at PHC
Launched by MEDTRONIC - MITG · Oct 9, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Continuous Connected Patient Care (CCPC) trial is a research study designed to test a new device that helps monitor patients' vital signs continuously, both in the hospital and at home, after they have undergone non-cardiac surgery. The goal of this trial is to see how well this monitoring system works and how easy it is for patients to use. It will involve patients who are 19 years or older and have had surgery at St. Paul’s Hospital, requiring them to stay in the hospital afterward. Participants must live in British Columbia and have access to a Bell cellular network for the device to work effectively.
If you join this study, you will be provided with a monitoring device to wear, and you will be asked to answer some questions about your experience, either online or on paper. It's important to note that not everyone can participate; for example, patients who refuse to join, those who cannot consent due to sedation, or those without a caregiver to help with the device will not be eligible. This trial is not yet open for recruitment, but it aims to help improve patient care by ensuring that vital signs can be monitored conveniently during recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 19 years or older
- • Patients that have undergone a non-cardiac surgery at SPH requiring an inpatient hospital stay
- • Peri-op patients who are in the Surgical High Acuity Unit (SHAU) and those followed by Anesthesia Perioperative Outreach team on the ward
- • Living within British Columbia, Canada and in an area that is covered by Bell cellular network
- Exclusion Criteria:
- • Patient refusal
- • Lack of capacity to consent to the study (including having received sedative or general anesthetic within the past 24 hours)
- • Unable to use (or does not have a caregiver who can help put on) study monitoring device at home
- • Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone
- • No access to cell phone nor landline at home to receive follow-ups
- • Preoperatively known to be discharged to a nursing home or rehabilitation facility
- • Known allergic reactions to any part material of study devices
About Medtronic Mitg
Medtronic - Minimally Invasive Therapies Group (MITG) is a leading global sponsor focused on advancing minimally invasive surgical techniques and technologies to improve patient outcomes and optimize healthcare delivery. Committed to innovation and excellence, MITG develops a range of products and solutions that enhance surgical precision and efficiency, catering to a diverse array of medical conditions. Through rigorous clinical trials and research initiatives, Medtronic MITG aims to drive evidence-based practices in healthcare, ensuring that patients benefit from the latest advancements in minimally invasive procedures.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported